AmMax Bio licenses Lonza’s ADC tech to advance AML candidate AMB-104
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
Subscribe To Our Newsletter & Stay Updated